Calithera Biosciences, Inc.
Calithera Biosciences, Inc. (CALA) Stock Competitors & Peer Comparison
See (CALA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CALA | $0.00 | +200.00% | 487 | N/A | -$3.97 | N/A |
| VRTX | $445.31 | -0.28% | 113.6B | 29.19 | $15.32 | N/A |
| REGN | $754.90 | -2.30% | 80.8B | 18.73 | $41.49 | +0.46% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $738.52 | +1.13% | 46B | 37.93 | $19.59 | N/A |
| ALNY | $321.52 | -2.83% | 43.6B | 141.74 | $2.32 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $162.60 | -0.56% | 35.5B | -27.34 | -$6.03 | N/A |
| UTHR | $569.19 | -4.01% | 25B | 20.47 | $27.86 | N/A |
| BNTX | $88.03 | -0.96% | 22.5B | -16.50 | -$5.42 | N/A |
Stock Comparison
CALA vs VRTX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, VRTX has a market cap of 113.6B. Regarding current trading prices, CALA is priced at $0.00, while VRTX trades at $445.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 29.19. In terms of profitability, CALA's ROE is -1.31%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, CALA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check VRTX's competition here
CALA vs REGN Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, REGN has a market cap of 80.8B. Regarding current trading prices, CALA is priced at $0.00, while REGN trades at $754.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 18.73. In terms of profitability, CALA's ROE is -1.31%, compared to REGN's ROE of +0.15%. Regarding short-term risk, CALA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check REGN's competition here
CALA vs VRNA Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CALA is priced at $0.00, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CALA's ROE is -1.31%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, CALA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check VRNA's competition here
CALA vs ARGX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ARGX has a market cap of 46B. Regarding current trading prices, CALA is priced at $0.00, while ARGX trades at $738.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 37.93. In terms of profitability, CALA's ROE is -1.31%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, CALA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ARGX's competition here
CALA vs ALNY Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ALNY has a market cap of 43.6B. Regarding current trading prices, CALA is priced at $0.00, while ALNY trades at $321.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 141.74. In terms of profitability, CALA's ROE is -1.31%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, CALA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ALNY's competition here
CALA vs SGEN Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CALA is priced at $0.00, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CALA's ROE is -1.31%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CALA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check SGEN's competition here
CALA vs INSM Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, INSM has a market cap of 35.5B. Regarding current trading prices, CALA is priced at $0.00, while INSM trades at $162.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -27.34. In terms of profitability, CALA's ROE is -1.31%, compared to INSM's ROE of -1.68%. Regarding short-term risk, CALA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check INSM's competition here
CALA vs UTHR Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, UTHR has a market cap of 25B. Regarding current trading prices, CALA is priced at $0.00, while UTHR trades at $569.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 20.47. In terms of profitability, CALA's ROE is -1.31%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CALA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check UTHR's competition here
CALA vs BNTX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, BNTX has a market cap of 22.5B. Regarding current trading prices, CALA is priced at $0.00, while BNTX trades at $88.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -16.50. In terms of profitability, CALA's ROE is -1.31%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, CALA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check BNTX's competition here
CALA vs RPRX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, RPRX has a market cap of 20.8B. Regarding current trading prices, CALA is priced at $0.00, while RPRX trades at $48.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 27.24. In terms of profitability, CALA's ROE is -1.31%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CALA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check RPRX's competition here
CALA vs BGNE Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CALA is priced at $0.00, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CALA's ROE is -1.31%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, CALA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check BGNE's competition here
CALA vs ROIV Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ROIV has a market cap of 19.9B. Regarding current trading prices, CALA is priced at $0.00, while ROIV trades at $27.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -23.79. In terms of profitability, CALA's ROE is -1.31%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, CALA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ROIV's competition here
CALA vs MRNA Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, MRNA has a market cap of 19.8B. Regarding current trading prices, CALA is priced at $0.00, while MRNA trades at $48.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -6.89. In terms of profitability, CALA's ROE is -1.31%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, CALA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check MRNA's competition here
CALA vs RVMD Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, RVMD has a market cap of 19.5B. Regarding current trading prices, CALA is priced at $0.00, while RVMD trades at $98.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -16.58. In terms of profitability, CALA's ROE is -1.31%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, CALA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check RVMD's competition here
CALA vs INCY Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, INCY has a market cap of 18.8B. Regarding current trading prices, CALA is priced at $0.00, while INCY trades at $93.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 14.71. In terms of profitability, CALA's ROE is -1.31%, compared to INCY's ROE of +0.29%. Regarding short-term risk, CALA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check INCY's competition here
CALA vs DNA-WT Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CALA is priced at $0.00, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CALA's ROE is -1.31%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, CALA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check DNA-WT's competition here
CALA vs GMAB Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, GMAB has a market cap of 16.8B. Regarding current trading prices, CALA is priced at $0.00, while GMAB trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 17.68. In terms of profitability, CALA's ROE is -1.31%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, CALA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check GMAB's competition here
CALA vs BBIO Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, BBIO has a market cap of 14.4B. Regarding current trading prices, CALA is priced at $0.00, while BBIO trades at $73.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -19.70. In terms of profitability, CALA's ROE is -1.31%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, CALA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check BBIO's competition here
CALA vs SMMT Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, SMMT has a market cap of 14.1B. Regarding current trading prices, CALA is priced at $0.00, while SMMT trades at $18.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -13.14. In terms of profitability, CALA's ROE is -1.31%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, CALA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check SMMT's competition here
CALA vs ASND Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ASND has a market cap of 14B. Regarding current trading prices, CALA is priced at $0.00, while ASND trades at $225.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -52.59. In terms of profitability, CALA's ROE is -1.31%, compared to ASND's ROE of +1.28%. Regarding short-term risk, CALA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ASND's competition here
CALA vs KRTX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CALA is priced at $0.00, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CALA's ROE is -1.31%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CALA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check KRTX's competition here
CALA vs IONS Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, CALA is priced at $0.00, while IONS trades at $74.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -31.57. In terms of profitability, CALA's ROE is -1.31%, compared to IONS's ROE of -0.69%. Regarding short-term risk, CALA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check IONS's competition here
CALA vs MDGL Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, MDGL has a market cap of 12.2B. Regarding current trading prices, CALA is priced at $0.00, while MDGL trades at $529.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -41.26. In terms of profitability, CALA's ROE is -1.31%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, CALA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check MDGL's competition here
CALA vs EXEL Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, CALA is priced at $0.00, while EXEL trades at $43.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 15.84. In terms of profitability, CALA's ROE is -1.31%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, CALA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check EXEL's competition here
CALA vs JAZZ Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, JAZZ has a market cap of 11.6B. Regarding current trading prices, CALA is priced at $0.00, while JAZZ trades at $186.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is -32.24. In terms of profitability, CALA's ROE is -1.31%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, CALA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check JAZZ's competition here
CALA vs RNAM Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CALA is priced at $0.00, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CALA's ROE is -1.31%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CALA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check RNAM's competition here
CALA vs BMRN Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, CALA is priced at $0.00, while BMRN trades at $56.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 31.80. In terms of profitability, CALA's ROE is -1.31%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, CALA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check BMRN's competition here
CALA vs RXDX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CALA is priced at $0.00, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CALA's ROE is -1.31%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CALA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check RXDX's competition here
CALA vs ARWR Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ARWR has a market cap of 8.8B. Regarding current trading prices, CALA is priced at $0.00, while ARWR trades at $62.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is 39.32. In terms of profitability, CALA's ROE is -1.31%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, CALA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ARWR's competition here
CALA vs AXSM Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, AXSM has a market cap of 8.8B. Regarding current trading prices, CALA is priced at $0.00, while AXSM trades at $169.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -46.68. In terms of profitability, CALA's ROE is -1.31%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, CALA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check AXSM's competition here
CALA vs IMGN Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CALA is priced at $0.00, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CALA's ROE is -1.31%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CALA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check IMGN's competition here
CALA vs PCVX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, CALA is priced at $0.00, while PCVX trades at $57.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -10.39. In terms of profitability, CALA's ROE is -1.31%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, CALA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check PCVX's competition here
CALA vs TECH Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, TECH has a market cap of 8.4B. Regarding current trading prices, CALA is priced at $0.00, while TECH trades at $52.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 100.91. In terms of profitability, CALA's ROE is -1.31%, compared to TECH's ROE of +0.04%. Regarding short-term risk, CALA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check TECH's competition here
CALA vs BPMC Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CALA is priced at $0.00, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CALA's ROE is -1.31%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, CALA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check BPMC's competition here
CALA vs CYTK Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, CALA is priced at $0.00, while CYTK trades at $67.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -10.19. In terms of profitability, CALA's ROE is -1.31%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, CALA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CYTK's competition here
CALA vs CERE Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CALA is priced at $0.00, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, CALA's ROE is -1.31%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CALA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CERE's competition here
CALA vs NUVL Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, CALA is priced at $0.00, while NUVL trades at $104.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -18.06. In terms of profitability, CALA's ROE is -1.31%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, CALA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check NUVL's competition here
CALA vs HALO Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, HALO has a market cap of 7.7B. Regarding current trading prices, CALA is priced at $0.00, while HALO trades at $64.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 25.55. In terms of profitability, CALA's ROE is -1.31%, compared to HALO's ROE of +0.93%. Regarding short-term risk, CALA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check HALO's competition here
CALA vs KRYS Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, CALA is priced at $0.00, while KRYS trades at $255.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 37.80. In terms of profitability, CALA's ROE is -1.31%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CALA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check KRYS's competition here
CALA vs ABVX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, CALA is priced at $0.00, while ABVX trades at $115.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -20.60. In terms of profitability, CALA's ROE is -1.31%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, CALA is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ABVX's competition here
CALA vs MTSR Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CALA is priced at $0.00, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CALA's ROE is -1.31%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, CALA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check MTSR's competition here
CALA vs IBRX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, CALA is priced at $0.00, while IBRX trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -18.79. In terms of profitability, CALA's ROE is -1.31%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, CALA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check IBRX's competition here
CALA vs KYMR Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, CALA is priced at $0.00, while KYMR trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -23.02. In terms of profitability, CALA's ROE is -1.31%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, CALA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check KYMR's competition here
CALA vs MRUS Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CALA is priced at $0.00, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CALA's ROE is -1.31%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, CALA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check MRUS's competition here
CALA vs PRAX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, CALA is priced at $0.00, while PRAX trades at $316.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -23.67. In terms of profitability, CALA's ROE is -1.31%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, CALA is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check PRAX's competition here
CALA vs ACLX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CALA is priced at $0.00, while ACLX trades at $114.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.19. In terms of profitability, CALA's ROE is -1.31%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CALA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ACLX's competition here
CALA vs PTGX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, CALA is priced at $0.00, while PTGX trades at $102.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is -50.57. In terms of profitability, CALA's ROE is -1.31%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, CALA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check PTGX's competition here
CALA vs BLTE Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, CALA is priced at $0.00, while BLTE trades at $155.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -72.40. In terms of profitability, CALA's ROE is -1.31%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, CALA is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check BLTE's competition here
CALA vs RETA Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CALA is priced at $0.00, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, CALA's ROE is -1.31%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CALA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check RETA's competition here
CALA vs RYTM Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, CALA is priced at $0.00, while RYTM trades at $87.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -28.33. In terms of profitability, CALA's ROE is -1.31%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, CALA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check RYTM's competition here
CALA vs ALKS Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ALKS has a market cap of 5.8B. Regarding current trading prices, CALA is priced at $0.00, while ALKS trades at $34.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 24.51. In terms of profitability, CALA's ROE is -1.31%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, CALA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ALKS's competition here
CALA vs COGT Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, CALA is priced at $0.00, while COGT trades at $34.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -16.31. In terms of profitability, CALA's ROE is -1.31%, compared to COGT's ROE of -1.00%. Regarding short-term risk, CALA is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check COGT's competition here
CALA vs PTCT Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, CALA is priced at $0.00, while PTCT trades at $68.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 8.01. In terms of profitability, CALA's ROE is -1.31%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, CALA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check PTCT's competition here
CALA vs SRRK Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, CALA is priced at $0.00, while SRRK trades at $48.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -15.00. In terms of profitability, CALA's ROE is -1.31%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, CALA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check SRRK's competition here
CALA vs CGON Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, CALA is priced at $0.00, while CGON trades at $66.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -32.11. In terms of profitability, CALA's ROE is -1.31%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CALA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CGON's competition here
CALA vs CDTX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CALA is priced at $0.00, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CALA's ROE is -1.31%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, CALA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CDTX's competition here
CALA vs ABCM Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CALA is priced at $0.00, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CALA's ROE is -1.31%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CALA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ABCM's competition here
CALA vs ISEE Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CALA is priced at $0.00, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CALA's ROE is -1.31%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CALA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ISEE's competition here
CALA vs CELC Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CELC has a market cap of 5.5B. Regarding current trading prices, CALA is priced at $0.00, while CELC trades at $111.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -29.80. In terms of profitability, CALA's ROE is -1.31%, compared to CELC's ROE of -2.03%. Regarding short-term risk, CALA is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CELC's competition here
CALA vs CAI Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, CALA is priced at $0.00, while CAI trades at $18.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CAI's P/E ratio is -5.94. In terms of profitability, CALA's ROE is -1.31%, compared to CAI's ROE of +0.25%. Regarding short-term risk, CALA is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CAI's competition here
CALA vs TGTX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, TGTX has a market cap of 5.4B. Regarding current trading prices, CALA is priced at $0.00, while TGTX trades at $33.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 12.12. In terms of profitability, CALA's ROE is -1.31%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, CALA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check TGTX's competition here
CALA vs CNTA Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CNTA has a market cap of 5.4B. Regarding current trading prices, CALA is priced at $0.00, while CNTA trades at $39.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -21.09. In terms of profitability, CALA's ROE is -1.31%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, CALA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CNTA's competition here
CALA vs FBIOX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, CALA is priced at $0.00, while FBIOX trades at $25.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas FBIOX's P/E ratio is N/A. In terms of profitability, CALA's ROE is -1.31%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, CALA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check FBIOX's competition here
CALA vs APLS Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, CALA is priced at $0.00, while APLS trades at $40.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 224.39. In terms of profitability, CALA's ROE is -1.31%, compared to APLS's ROE of +0.08%. Regarding short-term risk, CALA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check APLS's competition here
CALA vs ERAS Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ERAS has a market cap of 5.2B. Regarding current trading prices, CALA is priced at $0.00, while ERAS trades at $16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -37.73. In terms of profitability, CALA's ROE is -1.31%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, CALA is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ERAS's competition here
CALA vs IMVT Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, IMVT has a market cap of 5.1B. Regarding current trading prices, CALA is priced at $0.00, while IMVT trades at $23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -9.40. In terms of profitability, CALA's ROE is -1.31%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, CALA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check IMVT's competition here
CALA vs TERN Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CALA is priced at $0.00, while TERN trades at $52.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.25. In terms of profitability, CALA's ROE is -1.31%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CALA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check TERN's competition here
CALA vs MIRM Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, CALA is priced at $0.00, while MIRM trades at $93.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -201.32. In terms of profitability, CALA's ROE is -1.31%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, CALA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check MIRM's competition here
CALA vs APGE Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, APGE has a market cap of 4.7B. Regarding current trading prices, CALA is priced at $0.00, while APGE trades at $83.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -19.96. In terms of profitability, CALA's ROE is -1.31%, compared to APGE's ROE of -0.37%. Regarding short-term risk, CALA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check APGE's competition here
CALA vs CRSP Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CRSP has a market cap of 4.7B. Regarding current trading prices, CALA is priced at $0.00, while CRSP trades at $47.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -7.54. In terms of profitability, CALA's ROE is -1.31%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, CALA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CRSP's competition here
CALA vs FOLD Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CALA is priced at $0.00, while FOLD trades at $14.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -160.44. In terms of profitability, CALA's ROE is -1.31%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CALA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check FOLD's competition here
CALA vs AKRO Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CALA is priced at $0.00, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CALA's ROE is -1.31%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, CALA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check AKRO's competition here
CALA vs XENE Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, CALA is priced at $0.00, while XENE trades at $56.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -13.00. In terms of profitability, CALA's ROE is -1.31%, compared to XENE's ROE of -0.56%. Regarding short-term risk, CALA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check XENE's competition here
CALA vs CORT Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CORT has a market cap of 4.5B. Regarding current trading prices, CALA is priced at $0.00, while CORT trades at $41.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 51.20. In terms of profitability, CALA's ROE is -1.31%, compared to CORT's ROE of +0.15%. Regarding short-term risk, CALA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CORT's competition here
CALA vs ALPN Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CALA is priced at $0.00, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CALA's ROE is -1.31%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CALA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ALPN's competition here
CALA vs OPT Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CALA is priced at $0.00, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, CALA's ROE is -1.31%, compared to OPT's ROE of +0.88%. Regarding short-term risk, CALA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check OPT's competition here
CALA vs MRTX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CALA is priced at $0.00, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CALA's ROE is -1.31%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CALA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check MRTX's competition here
CALA vs LGND Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, LGND has a market cap of 4B. Regarding current trading prices, CALA is priced at $0.00, while LGND trades at $197.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 32.62. In terms of profitability, CALA's ROE is -1.31%, compared to LGND's ROE of +0.14%. Regarding short-term risk, CALA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check LGND's competition here
CALA vs CRNX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, CALA is priced at $0.00, while CRNX trades at $35.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -7.39. In terms of profitability, CALA's ROE is -1.31%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, CALA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CRNX's competition here
CALA vs VKTX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, CALA is priced at $0.00, while VKTX trades at $32.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -10.33. In terms of profitability, CALA's ROE is -1.31%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, CALA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check VKTX's competition here
CALA vs ACAD Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, CALA is priced at $0.00, while ACAD trades at $21.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 9.70. In terms of profitability, CALA's ROE is -1.31%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, CALA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ACAD's competition here
CALA vs NAMS Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, NAMS has a market cap of 3.8B. Regarding current trading prices, CALA is priced at $0.00, while NAMS trades at $32.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -19.08. In terms of profitability, CALA's ROE is -1.31%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, CALA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check NAMS's competition here
CALA vs RYZB Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CALA is priced at $0.00, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CALA's ROE is -1.31%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CALA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check RYZB's competition here
CALA vs CBAY Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CALA is priced at $0.00, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CALA's ROE is -1.31%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CALA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CBAY's competition here
CALA vs KNSA Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, CALA is priced at $0.00, while KNSA trades at $47.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 64.17. In terms of profitability, CALA's ROE is -1.31%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, CALA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check KNSA's competition here
CALA vs EWTX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, CALA is priced at $0.00, while EWTX trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -20.33. In terms of profitability, CALA's ROE is -1.31%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, CALA is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check EWTX's competition here
CALA vs SWTX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CALA is priced at $0.00, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CALA's ROE is -1.31%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, CALA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check SWTX's competition here
CALA vs LEGN Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, CALA is priced at $0.00, while LEGN trades at $19.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -11.76. In terms of profitability, CALA's ROE is -1.31%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, CALA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check LEGN's competition here
CALA vs LQDA Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, CALA is priced at $0.00, while LQDA trades at $37.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is -46.84. In terms of profitability, CALA's ROE is -1.31%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, CALA is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check LQDA's competition here
CALA vs DNTH Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, DNTH has a market cap of 3.2B. Regarding current trading prices, CALA is priced at $0.00, while DNTH trades at $84.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -20.13. In terms of profitability, CALA's ROE is -1.31%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, CALA is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check DNTH's competition here
CALA vs TLX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, TLX has a market cap of 3.1B. Regarding current trading prices, CALA is priced at $0.00, while TLX trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas TLX's P/E ratio is -462.00. In terms of profitability, CALA's ROE is -1.31%, compared to TLX's ROE of -0.02%. Regarding short-term risk, CALA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check TLX's competition here
CALA vs DNLI Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, CALA is priced at $0.00, while DNLI trades at $19.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -6.63. In terms of profitability, CALA's ROE is -1.31%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, CALA is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check DNLI's competition here
CALA vs CPRX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, CPRX has a market cap of 3.1B. Regarding current trading prices, CALA is priced at $0.00, while CPRX trades at $24.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 14.77. In terms of profitability, CALA's ROE is -1.31%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CALA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check CPRX's competition here
CALA vs ARQT Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, ARQT has a market cap of 3B. Regarding current trading prices, CALA is priced at $0.00, while ARQT trades at $23.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas ARQT's P/E ratio is -185.38. In terms of profitability, CALA's ROE is -1.31%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, CALA is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check ARQT's competition here
CALA vs TARS Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, TARS has a market cap of 3B. Regarding current trading prices, CALA is priced at $0.00, while TARS trades at $70.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas TARS's P/E ratio is -44.16. In terms of profitability, CALA's ROE is -1.31%, compared to TARS's ROE of -0.20%. Regarding short-term risk, CALA is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check TARS's competition here
CALA vs DYN Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, DYN has a market cap of 3B. Regarding current trading prices, CALA is priced at $0.00, while DYN trades at $17.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas DYN's P/E ratio is -5.22. In terms of profitability, CALA's ROE is -1.31%, compared to DYN's ROE of -0.61%. Regarding short-term risk, CALA is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check DYN's competition here
CALA vs SYRE Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, SYRE has a market cap of 3B. Regarding current trading prices, CALA is priced at $0.00, while SYRE trades at $47.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -24.70. In terms of profitability, CALA's ROE is -1.31%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, CALA is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check SYRE's competition here
CALA vs TVTX Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, TVTX has a market cap of 2.9B. Regarding current trading prices, CALA is priced at $0.00, while TVTX trades at $31.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas TVTX's P/E ratio is -59.29. In terms of profitability, CALA's ROE is -1.31%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, CALA is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check TVTX's competition here
CALA vs VERA Comparison April 2026
CALA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALA stands at 487. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, CALA is priced at $0.00, while VERA trades at $40.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALA currently has a P/E ratio of N/A, whereas VERA's P/E ratio is -8.69. In terms of profitability, CALA's ROE is -1.31%, compared to VERA's ROE of -0.60%. Regarding short-term risk, CALA is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for CALA.Check VERA's competition here